pembrolizumab is safe and effective and substantially increases overall survival in ansclc patients
Published 5 years ago • 1.6K plays • Length 5:51Download video MP4
Download video MP3
Similar videos
-
0:51
pembrolizumab increases long-term survival in patients with advanced nsclc
-
6:04
immunotherapy significantly increases the number of patients free from bowel cancer
-
5:13
immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
-
3:44
pembrolizumab plus chemo shows prolonged os and pfs improvement vs chemo for squamous nsclc
-
2:31
pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
-
1:26
pembrolizumab plus docetaxel used to treat patients with mcrpc
-
7:04
combined immuno-chemotherapy improves survival and responses in metastatic lung cancer
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
9:33
five-year long-term overall survival for patients with advanced nsclc treated with pembrolizumab...
-
6:00
ramucirumab plus pembrolizumab improves os in advanced nsclc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
2:10
pembrolizumab, tumor response, and survival in advanced melanoma
-
2:11
pembrolizumab works better than chemotherapy alone as initial treatment for nsclc
-
1:41
pembrolizumab improves 5-year survival in advanced nsclc in keynote-001
-
4:33
durvalumab following chemoradiotherapy improves survival in patients with limited-stage small-ce...
-
5:49
nivolumab extends survival for patients with the most common lung cancer
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
4:50
comment: reasonable to conclude that pembrolizumab is non-inferior to chemotherapy